FDA Press Announcements · August 28, 2026 · Primary source
August 28, 2026 - FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder
Summary
FDA approved Mimrylo (rusfertide) on August 28, 2026 for adults with polycythemia vera whose disease has not been adequately controlled with existing therapies. Rusfertide is the first approved hepcidin-mimetic treatment for this rare blood disorder, targeting the hormone pathway that regulates iron and red blood cell production. The approval introduces a new drug into the market but the excerpt contains no information on CMS coverage, reimbursement codes, pricing, or fraud-and-abuse implications.
What this may mean
The FDA approval makes rusfertide eligible for prescribing by hematology and oncology providers treating polycythemia vera, triggering formulary, prior-authorization, and billing processes at health plans and hospitals. No NCD, LCD, J-code assignment, or reimbursement rate is disclosed in the excerpt, so downstream revenue-cycle and coverage implications remain unquantified at this stage. No FCA, AKS, or behavioral health compliance dimension is present.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Press Announcements · October 5, 2026FDA Seeks Public Input to Support Ibogaine ResearchScore 58
- FDA Press Announcements · October 24, 2026FDA Issues Final Guidance on Prescription Drug Apps and SoftwareScore 46
- FDA Press Announcements · September 22, 2026FDA Updates Regulations to Advance Innovative Alternatives to Animal TestingScore 40
- FDA Press Announcements · September 4, 2026September 4, 2026 - FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition ProductsScore 40
- FDA Press Announcements · August 28, 2026FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in AdultsScore 40
- FDA Press Announcements · September 4, 2026September 4, 2026 - FDA Grants Accelerated Approval to a New Breast Cancer TreatmentScore 32